Screener
Charles River Laboratories CRL Liabilities, Fair Value Disclosure
Liabilities, Fair Value Disclosure at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| Other assets measured at fair value: | ||||
| Life insurance policies | — | $75,331 | — | $75,331 |
| Total assets measured at fair value | — | $75,331 | — | $75,331 |
| Accrued liabilities measured at fair value: | ||||
| Contingent consideration | — | — | $22,500 | $22,500 |
| Other long-term liabilities measured at fair value: | ||||
| Contingent consideration | — | — | $22,500 | $22,500 |
| Total liabilities measured at fair value | — | — | $45,000 | $45,000 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's liabilities, fair value disclosure?
- Charles River Laboratories (CRL) reported liabilities, fair value disclosure of $45M in Q2 2026.
- What does liabilities, fair value disclosure mean?
- Liabilities, Fair Value Disclosure as reported by Charles River Laboratories International, Inc..
Ask your AI about Charles River Laboratories's liabilities, fair value disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude